Oncotelic Therapeutics (OTLC) Stock Price, News & Analysis

Company Overview

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs. The company has conducted early‐phase clinical studies in solid tumors and is exploring combination strategies with immune checkpoint inhibitors. Oncotelic’s research and development efforts are focused on expanding the potential of its oncolytic platform across multiple cancer indications and optimizing its diagnostic capabilities to support personalized treatment strategies.

Headquartered in Gaithersburg, Maryland, Oncotelic operates with a lean scientific and management team. Leadership is spearheaded by President and Chief Executive Officer Bryan M. Saltjian, Ph.D., who brings extensive experience in viral immunotherapy and biotechnology commercialization. Under his guidance, Oncotelic aims to advance its pipeline through clinical milestones and strategic partnerships that can bring its oncolytic and diagnostic innovations to the broader oncology community.

Key Stats

• Today's Range: $0.04 to $0.04
• 50-Day Range: $0.03 to $0.05
• 52-Week Range: $0.02 to $0.11
• Volume: 15,251 shs
• Average Volume: 276,422 shs
• Market Capitalization: $17.30 million
• P/E Ratio: 0.07
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Oncotelic Therapeutics Stock Analysis - MarketRank™

Oncotelic Therapeutics scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Oncotelic Therapeutics.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Oncotelic Therapeutics is 0.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.28.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oncotelic Therapeutics is 0.06, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.02.

Price to Book Value per Share Ratio

Oncotelic Therapeutics has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Oncotelic Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Oncotelic Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oncotelic Therapeutics has recently decreased by 99.90%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oncotelic Therapeutics does not currently pay a dividend.

Dividend Growth

Oncotelic Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Oncotelic Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oncotelic Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.22% of the stock of Oncotelic Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Oncotelic Therapeutics has minimal institutional ownership at this time.

OTLC Stock Analysis - Frequently Asked Questions

How have OTLC shares performed this year?

Oncotelic Therapeutics' stock was trading at $0.0775 at the start of the year. Since then, OTLC stock has decreased by 50.7% and is now trading at $0.0382.

How were Oncotelic Therapeutics' earnings last quarter?

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) posted its quarterly earnings data on Wednesday, April, 15th. The company reported $0.59 EPS for the quarter.

How do I buy shares of Oncotelic Therapeutics?

Shares of OTLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Oncotelic Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncotelic Therapeutics investors own include MariMed (MRMD), DSS (DSS), Cemex (CX), CohBar (CWBR),

Company Calendar

• Last Earnings: 4/15/2026
• Today: 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:OTLC
• CIK: 908259
• Web: www.mateon.com
• Phone: (650) 635-7000
• Fax: 650-635-7001
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.59
• Trailing P/E Ratio: 0.07
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $249.28 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: 350.62%
• Return on Assets: 210.10%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 0.07
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $70 thousand
• Price / Sales: 247.08
• Cash Flow: $0.56 per share
• Price / Cash Flow: 0.07
• Book Value: $0.59 per share
• Price / Book: 0.07

Miscellaneous

• Outstanding Shares: 443,480,000
• Free Float: 269,546,000
• Market Cap: $17.30 million
• Optionable: Not Optionable
• Beta: -0.54